Zydus Lifesciences informs about press release
Zydus Lifesciences has informed that it enclosed a copy of press release dated November 6, 2025, titled ‘Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of betathalassemia’.
The above information is a part of company’s filings submitted to BSE.
